NEU4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6017862	0.61	10/20
SCHEMBL6017850	0.60	9/20
SCHEMBL6018295	1.00	8/20
SCHEMBL6017871	0.96	8/20
SCHEMBL6018299	0.91	8/20
SCHEMBL6019140	0.83	8/20
SCHEMBL7117750	0.83	8/20
SCHEMBL7117753	0.83	8/20
SCHEMBL6018122	0.79	8/20
SCHEMBL6018006	0.79	8/20
SCHEMBL6018907	0.78	8/20
SCHEMBL6018255	0.77	8/20
SCHEMBL6018090	0.74	8/20
SCHEMBL6018036	0.74	8/20
SCHEMBL6017753	0.73	8/20
SCHEMBL6018868	0.73	8/20
SCHEMBL6017923	0.72	8/20
SCHEMBL6018525	0.72	8/20
SCHEMBL6018052	0.71	8/20
SCHEMBL6018286	0.71	8/20

Clinical trials — most relevant to NEU4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19	PHASE4	UNKNOWN
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI	PHASE4	COMPLETED
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza	PHASE3	ACTIVE_NOT_RECRUITING
Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model	PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
The Natural History of Sialidosis Type I	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Registry Gangliosidoses	nan	UNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Sialic Acid in Hepatocellular Carcinoma	nan	NOT_YET_RECRUITING
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan	nan	ACTIVE_NOT_RECRUITING
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease	nan	UNKNOWN
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Early Detection and Follow-Up of Patients With Fabry's Disease	nan	UNKNOWN
Blood Glycan Biomarkers in Women With Stage IV Breast Cancer	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NEU4 binder may also engage these)

Protein	Name	Similarity
Q8BZL1	—	0.988	Q8BZL1 →
NEU3	Sialidase-3	0.968	landscape →
D3KCC4	—	0.966	D3KCC4 →
A5YM72	—	0.962	A5YM72 →
Q5U4P2	—	0.962	Q5U4P2 →
Q9JMH7	—	0.962	Q9JMH7 →
Q2TA57	—	0.961	Q2TA57 →
Q96EY9	—	0.961	Q96EY9 →
Q62994	—	0.961	Q62994 →
Q561R2	—	0.960	Q561R2 →
O97859	—	0.959	O97859 →
A7MBM2	—	0.958	A7MBM2 →
Q9BG99	—	0.958	Q9BG99 →
A1L515	—	0.958	A1L515 →
P04087	—	0.958	P04087 →
FUT4	Alpha-(1,3)-fucosyltransferase 4	0.957	landscape →
Q0V8J4	—	0.956	Q0V8J4 →
Q6PAT0	—	0.956	Q6PAT0 →
Q5SZI1	—	0.956	Q5SZI1 →
P54777	—	0.955	P54777 →
P55101	—	0.955	P55101 →
Q96BM1	—	0.955	Q96BM1 →
Q99LC9	—	0.955	Q99LC9 →
Q9QYP0	—	0.954	Q9QYP0 →
Q14296	—	0.954	Q14296 →
Q659K9	—	0.954	Q659K9 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.954	landscape →
Q8IZY2	—	0.954	Q8IZY2 →
Q8IUL8	—	0.953	Q8IUL8 →
Q9TT93	—	0.953	Q9TT93 →